







SB 9200 is a Novel Broad-Spectrum Antiviral Agent Effective Against RSV and Flu







SB 9000
SB 9200





Induction of anti-viral response by SB 9000 and SB 9200



SB 9000 interacts directly with RIG-I





Anti-viral activity of SB 9000/SB 9200 in A549 cells




Anti-viral therapeutic or prophylactic activity of SB 9200 in infected airways



A.




B.






C.



D.



SB 9200 induces an anti-inflammatory response



Conclusions

- ❑ SB 9200 interacts with RIG-I
- ❑ SB 9200 activates IRF3 to produce anti-viral cytokines
- ❑ SB 9200 requires RIG-I for IFN- β response
- ❑ SB 9200 possesses therapeutic anti-viral activity against RSV and prophylactic anti-viral activity against flu in human lung epithelial (A549) cells
- ❑ SB 9200 possesses therapeutic anti-viral activity against RSV and prophylactic anti-viral activity against flu in the murine respiratory tract
- ❑ SB 9200 diminishes airway disease severity by reducing infection and lung inflammation

Host defense and virus clearance

Effective, but moderate
IFN-mediated
antiviral response
(optimized response)



Reduced inflammatory
response avoids
contributing to disease
pathogenesis

Acknowledgments

Washington State
University

Santanu Bose
Niraj K. Shil

Georgetown University
Medical Center

Brent E. Korba

University of Texas
Health Sciences Center

Te-Hung Chang



Radhakrishnan Iyer, Nezem Afdhal, Sreerupa Challa, Geeta Meher, S. Padmanabhan, Rayomand Gimi, Anjan Sheri, Sam Baskaran, Dillon Cleary, Leena Suppiah, Vishal Nair, Shenghua Zhou, Irek Nowak, Lakshmi Bhagat